Favipiravir, multiple-dose pharmacokinetics and tolerability in volunteers.
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2011
At a glance
- Drugs Favipiravir (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Toyama Chemical
- 17 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 02 Oct 2008 New trial record.